Nicox announces the presentation of NCX 667 scient
Post# of 301275
Press Release
Nicox announces the presentation of NCX 667 scientific data at AOPT 2017
New preclinical data demonstrate NCX 667's robust IOP lowering properties
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that preclinical results from its novel nitric oxide (NO) donating compound, NCX 667, were presented at the Association for Ocular Pharmacology and Therapeutics (AOPT) 13 th Scientific Meeting, held from February 16-19, 2017, in Florence, Italy. NCX 667, synthesized by Nicox, is the lead compound of a new class of next-generation stand-alone NO-donors, which are designed to optimize NO dosing and enable intraocular pressure (IOP) lowering in patients with open angle glaucoma (OAG) or ocular hypertension.
The AOPT 2017 abstract by Impagnatiello et al 1 presented preclinical results obtained with NCX 667 in rabbit and non-human primate models of ocular hypertension and glaucoma following single and repeated treatment schedules. NCX 667 appeared to lower IOP by 20% or more regardless of the specific model and animal species used. Furthermore, repeated acute dosing of NCX 667 elicits sustained IOP-lowering activity over time with no signs of tachyphylaxis or ocular discomfort.
Data from a variety of experimental animal models coupled with recent clinical studies strongly support an important role of NO in lowering IOP by enhancing aqueous humor drainage via the conventional outflow route.
Open angle glaucoma is a common ocular disorder affecting about 2% of the adult population over 40 years old and is the second-leading cause of blindness worldwide. 2
About NCX 667
Developed by Nicox, NCX 667 already demonstrated promising preclinical results in two preclinical models of ocular hypertension and glaucoma. In both models, NCX 667 appeared well-tolerated and effective in reducing intra-ocular pressure (IOP). These results were selected by the ARVO 2015 Annual Meeting Program Committee as a 'Hot Topic', as representing the newest and most innovative research being conducted.
Notes:
- NCX 667, a lead nitric oxide (NO)-donating compound for a new class of ocular hypotensive agents F. Impagnatiello 1 , E. Bastia 1 , N. Almirante 1 , C. Toris 2 , C. Lanzi 3 , E. Ongini 1 , E. Masini 3 , M.V.W Bergamini 4 1 Nicox Research Institute, Milan, Italy; 2 Department of Ophthalmology, Case Western Reserve University, Cleveland, OH, USA; 3 Department of NEUROFARBA, University of Florence, Florence, Italy; 4 Nicox Ophthalmics, Inc., Fort Worth, TX, USA
- Glaucoma, Open-angle - https://nei.nih.gov/eyedata/glaucoma , accessed February 13, 2017
About Nicox
Nicox is an international ophthalmic R&D company utilizing innovative science to maintain vision and improve ocular health. By leveraging its proprietary expertise in nitric oxide donation and other technologies, the Company is developing an extensive portfolio of novel therapies that target multiple ophthalmic conditions, including glaucoma. Nicox currently has two products at the pre-approval stage with the U.S. Food and Drug Administration (FDA) and a promising pipeline including next-generation stand-alone nitric-oxide donors, with the potential to treat a range of ophthalmic indications. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.
For more information on Nicox, its products or pipeline, please visit: www.nicox.com .
Analyst coverage
Bryan, Garnier & Co Hugo Solvet Paris, France Invest Securities Martial Descoutures Paris, France Gilbert Dupont Damien Choplain Paris, France Stifel Olivia Manser London, UK
Upcoming financial and business conferences
March 6-8 Cowen and Company 37 th Annual Health Care Conference Boston, US March 21-22 Oppenheimer 27 th Annual Healthcare Conference New York, US April 4-5 Needham's 16 th Annual Healthcare Conference New York, US May 30 Gilbert Dupont 15 th Annual Helthcare Conference Paris, France June 19-22 2017 BIO International Convention San Diego, US
| Contacts | |
| Nicox Gavin Spencer, Executive Vice President Corporate Development T +33 (0)4 97 24 53 00 communications@nicox.com | |
| Investor Relations Europe NewCap Julien Perez, Valentine Brouchot T +33 (0)1 44 71 94 94 nicox@newcap.eu | Media Relations United Kingdom Jonathan Birt T +44 7860 361 746 jonathan.birt@ymail.com |
| United States Argot Partners Melissa Forst T +1 (212) 600-1902 melissa@argotpartners.com | France NewCap Nicolas Merigeau T +33 (0)1 44 71 94 98 nicox@newcap.eu |
| United States Argot Partners Eliza Schleifstein T +1 (917) 763-8106 eliza@argotpartners.com | |
Disclaimer
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.
| Nicox S.A. Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T +33 (0)4 97 24 53 00 F +33 (0)4 97 24 53 99 |
PRESS RELEASE: http://hugin.info/143509/R/2079786/783084.pdf
(0)
(0)